Brief: Ose Immunotherapeutics' COVID-19 Vaccine Gets Approval For Phase 1 Clinical Trial

Ose Immunotherapeutics SA

01/04/2021 17:18

April 1 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * RECEIVES AUTHORIZATION FOR PHASE 1 CLINICAL TRIAL OF ITS
MULTI-TARGET MULTI-VARIANT COVID-19 VACCINE
    * TODAY ANNOUNCED THAT BELGIAN FEDERAL AGENCY FOR MEDICINES
AND
HEALTH PRODUCTS (AFMPS) AND BELGIAN ETHICS COMMITTEE APPROVED
PHASE 1 TRIAL EVALUATING ITS COVID-19 VACCINE
    * AGENCE FÉDÉRALE DES MÉDICAMENTS ET DES PRODUITS DE SANTÉ 
(AFMPS) AND BELGIAN ETHICS COMMITTEE APPROVED PHASE 1 TRIAL
EVALUATING ITS COVID-19 VACCINE, NAMED COVEPIT, ON 48 HEALTHY
VOLUNTEERS
    * FIRST SUBJECTS ARE EXPECTED TO BE ENROLLED SHORTLY

Source text for Eikon:  ID:nNDL7D6j9T 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))